Clinical trials: Advanced Incurable Solid Malignancy
Advanced Malignant Solid Neoplasm, C-Reactive Protein Measurement
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
This phase II trial studies how well anamorelin hydrochloride, physical activity, and nutritional counseling work in decreasing cancer-related fatigue in patients with incurable solid tumors that have spread to other parts of the…
- Conditions
- Advanced Malignant Solid Neoplasm, C-Reactive Protein Measurement, Cancer Fatigue, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03035409
- Testing
- Anamorelin Hydrochloride, Exercise Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced…
- Trial name
- NCT01525602
- Testing
- PLX3397, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 74 people
- Sponsor
- Daiichi Sankyo
Solid Tumor
Safety Study of PLX108-01 in Patients With Solid Tumors
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable…
- Trial name
- NCT01004861
- Testing
- PLX3397
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Daiichi Sankyo
Neoplasms
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
The primary objective of this trial is to determine the maximum tolerated dose (MTD)/optimal biological dose (OBD) of BI 905681 given as an intravenous infusion and to determine the recommended dose and dosing schedule for…
- Trial name
- NCT04147247
- Testing
- BI 905681
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim